Lung and colon cancer costs among chemotherapy patients after an FDA policy change.

e14578 Background: Emerging evidence of adverse events from erythropoietin-stimulating agents (ESAs) led FDA to add a black box warning to ESA labeling in March 2007, after which ESA use declined. ...